| Literature DB >> 17387528 |
M Axel Wollmer1, Kristel Sleegers, Martin Ingelsson, Cezary Zekanowski, Nathalie Brouwers, Aleksandra Maruszak, Fabienne Brunner, Kim-Dung Huynh, Lena Kilander, Rose-Marie Brundin, Marie Hedlund, Vilmantas Giedraitis, Anna Glaser, Sebastiaan Engelborghs, Peter P De Deyn, Elisabeth Kapaki, Magdalini Tsolaki, Makrina Daniilidou, Dimitra Molyva, George P Paraskevas, Dietmar R Thal, Maria Barcikowska, Jacek Kuznicki, Lars Lannfelt, Christine Van Broeckhoven, Roger M Nitsch, Christoph Hock, Andreas Papassotiropoulos.
Abstract
Alzheimer's disease (AD) is a genetically complex disorder, and several genes related to cholesterol metabolism have been reported to contribute to AD risk. To identify further AD susceptibility genes, we have screened genes that map to chromosomal regions with high logarithm of the odds scores for AD in full genome scans and are related to cholesterol metabolism. In a European screening sample of 115 sporadic AD patients and 191 healthy control subjects, we analyzed single nucleotide polymorphisms in 28 cholesterol-related genes for association with AD. The genes HMGCS2, FDPS, RAFTLIN, ACAD8, NPC2, and ABCG1 were associated with AD at a significance level of P < or = 0.05 in this sample. Replication trials in five independent European samples detected associations of variants within HMGCS2, FDPS, NPC2, or ABCG1 with AD in some samples (P = 0.05 to P = 0.005). We did not identify a marker that was significantly associated with AD in the pooled sample (n = 2864). Stratification of this sample revealed an APOE-dependent association of HMGCS2 with AD (P = 0.004). We conclude that genetic variants investigated in this study may be associated with a moderate modification of the risk for AD in some samples.Entities:
Mesh：
Substances：
Year: 2007 PMID： 17387528 DOI： 10.1007/s10048-007-0087-z
Source DB: PubMed Journal: Neurogenetics ISSN： 1364-6745 Impact factor: 3.017